vintoperol: structure given in first source; no information given that it is a vinca alkaloid; RN refers to (3alpha, 16alpha)-isomer; RN for compound without isomeric designation not available 12/90 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Vinca | genus | A plant genus of the family Apocynaceae.[MeSH] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 6917973 |
| CHEMBL ID | 2105559 |
| SCHEMBL ID | 332109 |
| MeSH ID | M0182125 |
| Synonym |
|---|
| rt-3003 |
| rgh-2981 |
| vintoperol |
| (3-alpha,16-alpha)-14,15-dihydro-21-nor-1,14-secoeburnamenin-20-ol |
| (-)-(1s,12bs)-1-ethyl-1,2,3,4,6,7,12,12b-octahydroindolo(2,3-a)quinolizine-1-methanol |
| rgh 2981 |
| vintoperol [inn] |
| 21-nor-1,14-secoeburnamenin-20-ol, 14,15-dihydro-, (3-alpha,16-alpha)- |
| vintoperolum [inn-latin] |
| rt 3003 |
| (-)-(1s,12bs)-1-ethyl-1-hydroxymethyl-1,2,3,4,6,7,12,12b-octahydroindolo(1,3-a)quinolizine |
| brn 4786095 |
| [(1s,12bs)-1-ethyl-3,4,6,7,12,12b-hexahydro-2h-indolo[2,3-a]quinolizin-1-yl]methanol |
| is7c3gtw01 , |
| unii-is7c3gtw01 |
| vintoperolum |
| 106498-99-1 |
| CHEMBL2105559 |
| SCHEMBL332109 |
| rt3003 , |
| ((1s,12bs)-1-ethyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-1-yl)methanol |
| Q27280878 |
| DTXSID001030624 |
| AKOS040749752 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Myoblastic toxicity is a major adverse effect caused by reactive oxygen species (ROS) when exercising heavily." | ( Antioxidative effects of whey protein on peroxide-induced cytotoxicity. Kong, B; Liu, N; Xu, R; Xu, X, 2011) | 0.37 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||